Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker and Clinical Evaluation of Bevacizumab (Avastin) to Determine the Role of Nitric Oxide in Anti-VEGF Therapy

NCT00416637 is registered in ClinicalTrials.gov with Herbert Hurwitz, MD as lead sponsor.

NCT NCT00416637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00416637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker and Clinical Evaluation of Bevacizumab (Avastin) to Determine the Role of Nitric Oxide in Anti-VEGF Therapy
Lead sponsor
Herbert Hurwitz, MD
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2004
Completion date
March 31, 2006
Enrollment
27 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific